Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/50474
Title: Efficacy and safety of Sinovac vaccine administered in patients undergoing hemodialysis
Authors: Akın, Davut
Özmen, Şehmus
Çalışkan, Ahmet
Sarı, Tuğba
Keywords: COVID-19
hemodialysis
treatment
Sinovac
vaccine
Dysfunction
Covid-19
Antibody
Call
Publisher: J Infection Developing Countries
Abstract: Introduction: COVID-19 disease is more serious and fatal in patients on dialysis treatment due to their immunosuppressive status. In this study, we aimed to evaluate the protection and safety of Sinovac vaccine, which is an inactivated vaccine, in patients undergoing hemodialysis.Methodology: A control group consisting of 220 hemodialysis patients (HD group) and 648 healthcare professionals who were healthy in our institution were included in the study. Quant II IgG anti-Spike antibody was measured 3 weeks after two doses of Sinovac vaccine were administered to both groups.Results: The antibody response after two doses of Sinovac vaccine was 85.2% in the HD group and 99.8% in the control group. The mean antibody level before vaccination in the HD group was 3.5 +/- 7.2 AU/mL and increased significantly 3 weeks after two doses of vaccine (mean 751 +/- 1196 AU/mL). The control group's mean antibody level after vaccination was 1723 +/- 1878 AU/mL. The mean antibody level after vaccination in the control group was significantly higher than the HD group (p < 0.0001). Despite higher levels of anti-Spike antibodies in the control group, post-vaccination antibody response was acceptable in both HD and control groups. The HD group was significantly older (mean 64 +/- 12 years) than the control group (36 +/- 10 years) (p < 0.0001).Conclusions: Although dialysis patients are immunocompromised, and some may not develop antibodies to the virus as strongly as healthy people, this study revealed that dialysis patients developed significant amounts of antibodies. Being old or on dialysis is an independent predictor of low antibody response to the Sinovac vaccine.
URI: https://doi.org/10.3855/jidc.17188
https://hdl.handle.net/11499/50474
ISSN: 1972-2680
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
jidc-016-1821.pdf405.69 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

54
checked on Aug 24, 2024

Download(s)

18
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.